PGRMC1 and endometrial cancer: Addressing these issues could provide sufficient detail so PGRMC agonists and antagonists could be developed into adjunct chemotherapeutic agents to treat ovarian and endometrial cancer and potentially many other cancers that express PGRMC family members.